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Colorectal cancer (CRC) is the most common cancer of the gastrointestinal tract. Different factors are responsible for the development 
of CRC. Transient Receptor Potential (TRP) which is an important component of calcium channel is associated with several patho-
logical conditions like cancer, neurodegenerative and cardiovascular diseases. Thirty members of the family of TRP ion channel 
in mammals have been determined till now. The aim of this study is to investigate TRPM, TRPV and TRPC gene expression levels 
in tumor tissues of CRC patients and to analyze the relationship of expression in tumor tissue of CRC with other known prognostic 
factors. Material and Methods: In this study, 93 CRC patients were included. The level of TRP gene expression in paraffin blocks 
of normal and cancerous colorectal tissue samples were studied at the level of mRNA with Real-time PCR. Results: The mRNA expres-
sion level of TRPV3, TRPV4, TRPV5, TRPM4 and TRPC6 genes in 37 female and 56 male patients diagnosed with CRC was revealed 
lower in tumor tissue as compared to normal tissue (p < 0.05). No statistically significant differences of mRNA expression levels 
of other TRP genes were found. Conclusions: TRP gene family like TRPV3, TRPV4, TRPV5, TRPM4 and TRPC6 may be thought 
as potential genes contributing to tumorigenesis as their expression decreases in CRC as compared to normal tissues.
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Colorectal cancer (CRC) is the most common can-
cer of the gastrointestinal tract. When evaluated along 
with rectal cancer, it ranks third as the most common 
cancer being observed after prostate and lung cancer 
in males and breast and lung cancer in females.
Genetic and environmental factors have an in-
fluential role in the development of CRC. Colorectal 
cancers are sporadic cancers even though the genetic 
predisposition is the most prominent risk factor in the 
majority of CRC. Cellular oncogenes, growth factors 
and receptors play a pivotal role in the development 
and growth of the CRC [1]. Alike other types of cancer, 
the development and progression of CRC also results 
from multiple genetic variations.
In most of the recently conducted studies, it has 
been found that that the ion channels play a critical 
role in cell proliferation. Blockade of these channels 
have been found to inhibit the development of cancer 
cells. Therefore ion channels have received a consi-
derable attention for therapeutic targets or prognostic 
biomarkers [2].
Being an ion channel, the family of Transient 
Receptor Potential (TRP) channels also comprise 
of seven different subsets. These are TRPC (ca-
nonical), TRPV (vanilloid), TRPM (melastatin), TRPML 
(mucolip), TRPP (polycys pyridine), TRPE (ankyrin 
transmembrane protein) and TRPN (nompc-like) which 
are associated with many pathological and physiologi-
cal functions. The relationship between TRP channels 
and cancer suggests that TRP is effective in many 
ongoing cancer processes like tumor invasion, mi-
gration, angioge nesis, apoptosis, differentiation and 
proliferation [3].
TRPM8, TRPM1, and TRPV6 are highly expressed 
in cancer cells and the amount of protein being 
expressed changes with progression from normal 
to tumorigenic and then to metastatic cells. The ex-
pression levels of some other TRP channels, including 
TRPC1, TRPC6, TRPM5 and TRPV1 is also increased 
in cancer tissues [4]. In a recent study, TRPC5 was 
found to be overproduced at the mRNA and protein 
levels in 5-Fu-resistant human CRC cells [5]. TRPM8, 
TRPM1 and TRPV1 are potential diagnostic markers 
for the prognosis of tumor development especially the 
degree of tumor aggression, and are potential targets 
for pharmaceutical interventions [4].
In this study, our aim is to find out gene expression 
levels of TRPM, TRPV, TRPC in cancerous tissues 
of colorectal cancer patients. We also target to analyze 
the relationship of expression in tumor tissue of CRC 
with other known prognostic factors like age, gender, 
stages of cancer, location and size of tumor, vascular 
invasion, perineural invasion, lymph node involvement 
and to investigate the usability as a therapeutic target.
MATERIALS AND METHODS
Selection of Patients. This study was performed 
during 2001–2010 and was undertaken in correlation 
with Department of Medical Oncology, Medical Faculty 
Hospital, Gaziantep University which was responsible 
for patients follow-up and their treatment and De-
partment of Pathology, Medical Faculty, Gaziantep 
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University which carried out pathological testing for 
different stages of colon cancer. This study was car-
ried out on 96 patients for which approval of the local 
ethics committee have been made retrospectively. 
Three out of 96 paraffin blocks of cancer tissue could 
not later be found and thus were excluded from the 
study. As a result, 93 cases of colon cancer were in-
cluded in this study.
The study of the patient demographics (age, gen-
der) and their different pathological features (tumor 
location, tumor size, histological type, differentiation, 
vascular and perineural invasion, involvement of lymph 
node), their different clinical stages, follow-up and their 
survival span have been registered in a standard form.
The stored paraffin blocks of 93 patients were ob-
tained from the archives of Department of Pathology, 
Faculty of Medicine, Gaziantep University for further 
study. The obtained samples were revaluated under 
light microscope. For each subject, separate paraffin 
blocks containing normal colon mucosa and infected 
colon cancerous tissue slides were selected.
RNA isolation from FFPE tissue. The total RNA 
was obtained from samples embedded in paraffin 
using RNeasy FFPE Kit (Qiagen Sample and Assay 
Technologies, Hilden, Germany, Cat. No: 73504). 
The quantity and integrity of the RNA was measured 
using Epoch Microplate Spectrophotometer (BioTek 
Instruments, Winooski, USA). After total RNA isolation 
and purification, samples were diluted to a concentra-
tion 50 ng/μl and stored at ‒80 °C until further use. 
RNA was converted to cDNA using Ipsogen Reverse 
Transcription-Dx Kit (Qiagen, Hilden, Germany, Lot 
no: 11–11–11) following the manufacturer’s protocol.
qPCR. Gene expression analysis was done on a Bio-
Mark™ HD System (Fluidigm Corporation, CA, USA). 
Samples were preamplified for 14 cycles using TaqMan® 
PreAmp Master Mix (Life Technologies, Foster City, CA, 
USA, Cat. No: 4391128) prior to real-time qPCR. Real-
time qPCR was done in BioMark 96.96 Dynamic Array 
(Fluidigm Corporation, CA, USA) using a set of TaqMan 
Gene Expression Assays (Life Technologies, Foster City, 
CA, USA, Cat. No: 4333458).
Statistical analysis. Real-time PCR was per-
formed using Fluidigm Dynamic Array along with 
BioMARK HD System and the gene expression mea-
surements and their data analysis was evaluated using 
Biogazel and qBasePLUS software program. ACTB 
was used as housekeeping gene for the normalization 
of the target genes.
Significance level was considered as p < 0.05 using 
Mann — Whitney test to analyze data. The dispersion 
values were also taken into account during compari-
son of Mann — Whitney average test values. When 
“datapoints” corresponding to the sample number 
measured in the assay fall below 12, significance test 
became quite sensitive and apart from the means, 
the distribution analysed for statistical significance 
of the test was probably found insufficient to gene-
rate a standard curve. Therefore, p value expressing 
the significance level of the test would be very high 
in this group and a significant comparison would not 
be expressed statistically.
RESULTS
A total of 93 patients including 37 women and 
56 men who were pathologically diagnosed with CRC 
were included in study. The ratio of men to women 
was 1.51. The patients were in the age group of 12–
87 years and the mean age of patients was found 
to be 60 ± 16.1 years. The general demographic, clinical 
and pathological characteristics are shown in Table 1. 
The smallest and largest tumor size was 1.5 cm and 
16 cm, respectively. The mean tumor size was 5.8 ± 
2.6 cm. According to the TNM classification, 9 (9.7%) 
patients were in stage I, 33 (35.5%) patients were 
in stage II, 26 (27.9%) patients were in stage III and the 
remaining 25 (26.9%) patients were in stage IV (Fig. 1).
Table 1. Distribution of general demographic, clinical and pathological 
characteristics of patients
Characteristics Number of patients, n (%)
Gender
Female 37 (39.8)
Male 56 (60.2)
Localization
Rectosigmoid 9 (9.7)
Rectum 12 (12.9)
Sigmoid 18 (19.4)
Right Colon 31 (33.3)
Left Colon 11 (11.8)
Transverse Colon 12 (12.9)
Histology
Adenocarcinoma 87 (93.5)
Mucinous carcinoma 6 (6.5)
Vascular invasion
Negative 78 (83.9)
Positive 15 (16.1)
Perineural invasion
Negative 86 (92.5)
Positive 7 (7.5)
Differentiation
Unknown 64 (68.8)
High 16 (17.2)
Medium 10 (10.8)
Less 3 (3.2)
Lymph node involvement
Negative 52 (55.9)
1–3 positive 29 (31.2)
4 and above positive 12 (12.9)
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Fig. 1. Distribution of patients according to TNM staging
Real-time PCR was performed using “Fluidigm Dy-
namic Array” along with BioMARK HD System and the 
gene expression measurements and their data analysis 
were evaluated using Biogazel and qBasePLUS soft-
ware program. ACTB was used as housekeeping gene 
for the normalization of the targets mentioned in Table 2.
210 Experimental Oncology 37, 208–212, 2015 (September)
The obtained gene expression data from normal 
and cancerous tissues of the same patient were 
compared (Fig. 2, Table 3). For this purpose, Real 
Time PCR was carried out of the mRNA obtained from 
93 patients for both tumor tissue and the normal ones. 
The expression of TRPV4, TRPM4, TRPV3, TRPC6 and 
TRPV5 in tumor tissues were found to have lesser gene 
expression as compared to normal tissues (p < 0.05). 
When expression levels of other TRP genes in tissues 
were compared, any significant difference was not 
found (p > 0.05).
Table 2. List of target genes to be investigated for gene expression in TRP 
channels
TRPA1 TRPC6 TRPM4 TRPV1 TRPV6
TRPC1 TRPC7 TRPM5 TRPV2 ACTB
TRPC3 TRPM1 TRPM6 TRPV3 −
TRPC4 TRPM2 TRPM7 TRPV4 −
TRPC5 TRPM3 TRPM8 TRPV5 −
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Fig. 2. Expression rate of tumor/normal tissues
Table 3. Comparison of gene expression data from normal and  cancero us 
tissues
Target 
gene
Tissue 
type
Gene expression 
level
Nu
m
be
r o
f p
at
ien
ts Tumor/normal ratio 
of gene expression
p
No
rm
al
ize
d 
m
ea
n 
va
lu
e
95
%
 C
I l
o-
we
r l
im
it
95
%
 C
I h
i-
gh
er
 li
m
it
M
ea
n 
va
lu
e
95
%
 C
I l
o-
we
r l
im
it
95
%
CI
 h
i-
gh
er
 li
m
it
TRPV4 Normal 1.000 0.656 1.524 76 0.116 0.06 0.222 3.26E-06Tumor 0.116 0.070 0.193 57
TRPM4 Normal 1.000 0.666 1.502 76 0.148 0.074 0.294 6.41E-05Tumor 0.148 0.082 0.266 47
TRPV3 Normal 1.000 0.655 1.527 73 0.169 0.085 0.336 1.28E-04Tumor 0.169 0.096 0.298 48
TRPC6 Normal 1.000 0.610 1.640 54 0.234 0.111 0.493 3.75E-03Tumor 0.234 0.132 0.415 41
TRPV5 Normal 1.000 0.651 1.536 55 0.303 0.152 0.605 1.44E-02Tumor 0.303 0.171 0.535 45
For the comparison of data related to different can-
cer stages, the number of patients in different groups 
was counted. In stage I, 9 patients; in stage II, 33 pa-
tients; in stage III, 26 patients; in stage IV, 25 patients 
were found out. However, for the comparison of aver-
age Mann — Whitney test values, the dispersion va-
lues should be taken into account. When “datapoints” 
corresponding to the sample number measured in the 
assay fall below 12, significance test became quite 
sensitive and apart from the means, the distribution 
analysed for statistical significance of the test was 
probably found insufficient to generate a standard 
curve. As the total number of patients in stage I was 9, 
therefore total number of patients in stage I and II were 
combined together in one group for their evaluation. 
As a result, stage I + II (42 patients), stage III (26 pa-
tients), stage IV (25 patients) were evaluated.
When the gene expression of cancerous tissues for 
different groups of patients for various stages as stage 
I + II, stage III and stage IV were compared with each 
other, there was no significant difference being found 
(p > 0.05).
The gene expression data obtained from the tumor 
tissues showed no significant differences statistically 
for tumor localisation, histological types, perineural 
invasion, vascular invasion, lymph node involvement, 
differentiation grade, patients gender, tumor size, 
status of recurrence and metastasis (p > 0.05).
DISCUSSION
The tumor formation involves the conversion of nor-
mal cells into hyperplastic, dysplastic, neoplastic and 
finally metastatic cancerous cells. This transformation 
is triggered by accumulation of certain mutated key 
signalling proteins which are encoded by oncogenes 
and tumor suppressor genes and as a result more 
aggressive cells are formed in order to compete with 
adverse local surroundings.
Expression of many proteins in cancer cells in-
creases or decreases as compared to normal cells. 
Some of the proteins which are encoded by oncogenes 
in majority and tumor suppressor genes play a crucial 
role in tumor growth and metastasis formation. Although 
the other proteins which are responsible for intracellular 
Ca2+ homeostasis take role in cancer progression, they 
are not associated with the development of tumor and/
or malignant cells [6–8](Rosado JA, 2004, #66).
Ca2+ is known to be a versatile carrier of cell regula-
ting information right from the formation of cell till its 
death. In recent studies, the role of calcium messen-
ger has been shown in several cell processes like cell 
division, cell motility, hormone secretion, metabolism, 
nervous system functioning, protein turnover, gene ex-
pression, developmental regulation and programmed 
cell death (apoptosis) [9–11].
Many members of the TRP family of Ca2+ and Na+ 
permeable channels show altered expression in can-
cer cells. The most studied proteins of TRP family are 
TRPM8, TRPV6, TRPM1 and TRPV1 [12–14]. To date, 
most changes involving TRP proteins do not involve 
mutations in the TRP gene but rather increased or de-
creased levels of expression of the normal (wild type) 
TRP protein, depending on the stage of the cancer
In a number of studies during the past 20 years, 
the expression and activity of TRP channels have been 
shown to change during cancer. In particular, TRPC, 
TRPM and TRPV have been reported to be associated 
with tumorigenesis and the growth and development 
of cancer cells [4]. As a result of these findings, TRP 
channel expressions have been proposed as means 
of prognosis or diagnosis of some cancers and targe-
ting of TRP channels have been proposed as a novel 
therapeutic strategy. For example, TRPV6 and 
TRPM8 have been proposed as an indicator (marker) 
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for prostate cancer development and TRPC6 as a the-
rapeutic target for oesophageal cancer [15–17].
As there is an association between TRPM, TRPV, 
TRPC of TRP family especially with malignant cell division 
and its progression, therefore we targeted to find out the 
gene expression levels of TRPM, TRPC and TRPV in CRC.
As far as we know, there is no literature that shows 
the gene expression of the extensive TRP gene family 
in CRC. Our study is the most comprehensive study 
on this issue and can pave a way to future works related 
to this. In literature we find only the expression study 
of TRPM8, TRPV1 and TRPV6 in CRC [18–21].
In this particular study, comparative study has been 
done between the gene expression data of cance-
rous tissues and normal tissues of the same patient 
suffering from CRC. According to the data obtained 
by using Real-time PCR reaction, the gene expression 
of TRPV4, TRPM4, TRPV3, TRPC6 and TRPV5 in can-
cerous tissues were found to be lower as compared 
to normal tissues (p < 0.05). When expression levels 
of other TRP genes in tissues were compared, no sig-
nificant difference was found statistically (p > 0.05).
Duncan et al. conducted a research on human me-
lanoma specimens using in situ hybridisation method 
and found that there was an increased TRPM1 expres-
sion in benign cells (melanocytic nevi) but there was 
no decrease in expression in primary melanoma as well 
as metastatic melanomas [22]. In our study, we also 
noticed a decrease in synthesis of TRPV4, TRPM4, 
TRPV3, TRPC6, TRPV5 in cancerous cells as compared 
to normal cells. TRPM1 showed a correlation with 
mRNA expression of melanocytic tumor progression, 
tumor thickness and its aggressiveness. In aggressive 
tumors, the mRNA expression of TRPM1 was contem-
plated to be lower or in an undetectable amount. These 
observations showed TRPM1 to be a tumor suppressor 
gene [23–25].
In the literature, there are no studies showing the 
expression of TRPM1 in CRC. We did not find any 
statistical difference of TRPM1 expression between 
tumor and normal tissues. This can be explained due 
to difference in tissues and diversity in cells.
Tsavaler et al. [21] investigated the relationship 
of TRPM8 expression between normal prostate tissue 
and prostate cancer tissue using in situ hybridisation 
analysis and concluded that there was a significant in-
crease of TRPM8 expression in prostate cancer tissues 
as compared to normal ones. TRPM8 expression was 
also studied in a number of non prostatic primary tumors 
of breast, colon, lung, and skin origin and a significant 
increase in its expression was found as compared to nor-
mal tissues. But in our study, there was no statistically 
significant difference of TRPM8 expression between 
tumor and normal tissues. We used RT-PCR from paraf-
fin blocks as a technique while Tsavaler et al. employed 
in situ hybridisation technique as method of analysis [21].
Suguro et al. [26] stated that diffuse large B-cell lym-
phoma accounts for 30% of non-Hodgkin’s lymphomas 
and noticed an increase of TRPM4 mRNA expression 
in CD5+. TRPM4 being one of the genes involved in the 
development of a “CD5 signature”, therefore it can 
be used as a prognostic clinical marker. In our study, 
TRPM4 expression was significantly lower in tumor 
tissue than in normal tissue. The reason for this may 
be due to difference in types of tissues.
Prawitt et al. [27] showed a sharp increase 
in TRPM5 mRNA expression in Wilms’ tumor and rhab-
domyosarcoma. There was no statistically significant 
difference of TRPM5 expression between tumor and 
normal tissues in our study.
As far as we know there has been no work done 
related to expression study of TRPV4, TRPV3, 
TRPV5 in CRC. We found a significant decrease 
in expression of TRPV4, TRPV3, TRPV5 in cancerous 
tissues than normal tissues. When compared with 
normal tissues or cells, the TRPV6 mRNA expression 
and/or TRPV6 protein expression shows a significant 
increase in prostate cancer tissue, human colon can-
cer, breast cancer, thyroid cancer and ovarian cancer 
tissues [18, 28–30]. As compared to normal tissues, 
increase in TRPV6 mRNA expression is observed 
in prostate cancer LNCaP and PC-3 cell line, CRC 
SW480 cell line and chronic myelogenous leukaemia 
K-562 cell lines [18, 19].
Immunohistochemical studies demonstrated that 
TRPV1 is expressed in adenocarcinoma [20]. Extracel-
lular polyamines which are agonists of TRPV1 are pre sent 
in considerable concentration in the gastrointestinal 
tract and at synapses and these levels increase during 
inflammation and cancer [31]. As compared to this, 
our study showed no significant difference statistically 
of TRPV1 expression between tumor and normal tissues.
The present study detected an increase in gene 
expression of TRPM8, TRV6, TRPV1 in CRC tissues 
as compared to normal tissues which makes it different 
from others studies. Channel expression in tumor is per-
formed by Western blot assay, immunohistochemical 
studies, RT-PCR or in situ hybridisation techniques. 
In order to prevent differences in results arising due 
to different operating methods, it is proposed to carry 
out comparison studies of these four techniques simul-
taneously from the same tissues. Gene expression stu-
dies should be carried out from paraffin blocks or fresh 
obtained tissues. We performed this study on paraffin 
blocks but further studies can be carried out using fresh 
tissues because ambient conditions during preparation 
of paraffin blocks can be an influential factor in channel 
expression studies. In addition, studies on fresh tis-
sues will certainly aid in better understanding of TRP 
expression pattern in CRC because of good correlation 
between mRNA and protein levels in fresh tissues.
In the present study there is markedly lower expres-
sion of TRPV4, TRPM4, TRPV3, TRPC6, TRPV5 in tu-
mor tissues of CRC than normal tissues. There may 
arise some questions related to present study like 
what about effectiveness of these genes in CRC, what 
are the related mechanisms related to its suppres-
sion. Epigenetic factors may be involved in the lower 
expression of TRPV4, TRPM4, TRPV3, TRPC6 and 
TRPV5 in these results.
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In conclusion, genes like TRPV4, TRPM4, TRPV3, 
TRPC6 and TRPV5 which are showing lower expression 
in CRC tissues are considered to be prominent gene 
candidates for potential tumor growth. This hypothesis 
needs to be supplemented and supported with further 
studies for its verification. New targeted therapeutic 
agents can be developed by employing TRP channel 
inhibitors in further studies.
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